List of Antibodies Companies in Japan - 22

Chiome Bioscience Inc. designs, develops, and sells monoclonal antibody products for medicine, diagnosis, testing, and life sciences. Chiome Bioscience is a clinical stage biotechnology company. Chiome's focus is on discovery and development of antibody-based therapeutics.

Chugai’s strength in R&D and antibody technologies continues on in global efforts for products and services for the benefit of patients. Chugai Pharma USA, Inc. (CPUSA), located in Berkeley Heights, NJ, is a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd. (Chugai). CPUSA supports the planning and execution of global and U.S. clinical programs for Chugai-originated, innovative new drug candidates. Chugai is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs in Chugai’s strategic fields of oncology, bone and joint diseases, and renal diseases as well as other therapeutic areas with serious unmet needs. Chugai develops its products independently from Roche until early Proof-of-Concept (PoC) for worldwide market, including U.S. For late stage clinical development and marketing outside of Japan, South Korea, and Taiwan, Chugai seeks for partnership with Roche, which has the first refusal rights to develop/sell Chugai products, or other third parties.

Bio Information is energy! COGNANO, Inc. is a venture to aim for computer-supported drug discovery. The big VHH data obtained from our own alpacas will lead us to a new drug discovery platform. Our goal is to optimize drug designing/development.

Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), with working on various activities together with global partners.

Epsilon Molecular Engineering (EME) Inc. is an evolutionary molecular engineering based biopharmaceutical drug discovery company. EME was established in 2016 as a venture company from Saitama University in Japan, and has proprietary technologies, unique cDNA display libraries of the heavy chain single domain antibodies (VHH) and cyclic peptides with large diversity (10^13-14), and high-throughput screening methods using next-generation sequence, FACS and Machine learning (Bioinformatics). EME is, currently, conducting several joint research projects, including COVID-19, and 17 ongoing inhouse projects in the arias of cancer, inflammation, and Alzheimer’s disease, etc.

弊社は、バイオ革命によって急速に発展し始めている再生医療分野において、体性幹細胞再生医薬品/iPSC再生医薬品の研究開発を行っているバイオベンチャーです。2015年6月には東証マザーズに上場。再生・細胞医薬品の開発・製造を世界で先駆けて取り組み、病で苦しむ患者さんに治療法を提供し希望を届けることを目標としています。 Our company is a bio venture which is doing R & D of somatic stem cell regenerating medicine / iPSC regenerating medicine in the regenerative medicine field which is rapidly developing by the bio-revolution. We were listed on TSE Mothers in June 2015. Our long-term object is to deliver hope to patients suffering from illness by providing treatment methods by pioneering the development and manufacture of regeneration and cellular medicines worldwide.

JCR Pharmaceutical is a global specialty pharmaceuticals company that is expanding possibilities for people with rare and genetic diseases worldwide. Our core values – reliability, confidence, and belief – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We continue to build upon our 49-year legacy in Japan while expanding our global footprint with trials in the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. We are leaders in developing therapies for rare conditions, including lysosomal storage disorders (LSDs). We are building on the development work we've done in Japan to expand our LSD pipeline: Our first-in-class proprietary technology, J-Brain Cargo®, enables us to develop therapies that cross the blood-brain barrier and penetrate the central nervous system (CNS). The CNS complications of diseases are often severe, resulting in developmental delays, an impact on cognition and, above all, poor prognosis, which affect patients' independence as well as the quality of life of patients and their caregivers. With J-Brain Cargo®, we seek to address the unresolved clinical challenges of LSDs and CNS-related disorders, including neurodegeneration, neuro-oncology, and neuro-inflammation conditions, by delivering the therapy to both the body and the brain. We will continuously try to create value by our unique J-Brain Cargo® technology platform toward our corporate philosophy: “contributing towards people’s healthcare through pharmaceutical products.” In addition to the in-house research activities, we think collaborative research and development work with other companies are also important. The value of our technology platform will be increased by integrating ours with other technologies and by implementing J-Brain Cargo® within other companies’ products.

Kidswell Bio Corporation (KWB), formerly known as Gene Techno Science, has been growing by leveraging our expertise in Biosimilar field in Japan. By 2024, four BS products were brought to market by our partner pharmaceutical companies as outcomes of co-developments between the companies and KWB. Besides, KWB has engaged in research and development for regenerative medicine with stem cells from human exfoliated deciduous teeth (SHED) since 2019, which targeted pediatric diseases, orphan disease and intractable disease with the aim of achieving comprehensive healthcare solutions for patients suffering from these diseases as well as for their families and caregivers. On the 1st of April 2024, the regenerative medicine business became independent as S-Quatre Corporation (SQ). KWB and SQ lead biosimilar business and regenerative medicine business　respectively, and grow together as two pillars of Kidswell Bio group. キッズウェル・バイオ株式会社(旧株式会社ジーンテクノサイエンス)はバイオシミラー医薬品事業により成長してきた。パートナー製薬企業との共同開発の結果、2024年までに4つのバイオシミラー製品を日本にて上市させている。一方で、2019年からは、乳歯由来歯髄幹細胞を用いた再生医療の研究開発に着手し、希少疾患、難病に加えて、小児疾患を重点的なターゲットと定め、患者様、及びそのご家族や介護者の方を含めた包括的なケアを目指した研究開発を行なってきた。KWBは2024年4月1日にこの再生医療事業を専門に行なう子会社である株式会社S-Quatreを設立し、現在はキッズウェル・バイオグループとしてバイオシミラーと再生医療の両事業を展開している。

Kissei Pharmaceutical - Approaching R&D with Passion and Creativity “Pharmaceutical company cannot exist without R&D.” These words have been passed down at Kissei ever since the company was founded. They show that R&D is an essential and central part of our work, The phrase also expresses the passion of each and every Kissei Pharmaceutical - Kissei employee for the development of new innovative drugs, in the hope that those drugs will help as many people as possible recover as quickly as possible from disease and live lives full of laughter and joy. We aim to develop and supply innovative pharmaceutical products that contribute to the improvement of medicine and the health of people around the world by aggressive incorporation of leading-edge technology and collaborations with our foreign and domestic partners.

KM Biologics' history of vaccine production started with the smallpox vaccine over a half century ago. Since then, we have produced many vaccines including those for typhoid and typhus, and have contributed to the eradication of infectious diseases in Japan. In recent years, through collaborating with companies and universities in Japan and overseas, we have been working on the development of new vaccines such as cell culture-derived influenza vaccines and DPT-based combined vaccines.

Metagen Therapeutics, Inc. is a drug discovery and development company that leverages the power of gut microbiome design cultivated in Metabologenomics, Inc. We are eager for partnerships in pharmaceutical, healthcare, functional food, and academia that envisions creating future businesses with one of the best microbiome scientist teams. For inquiries, please contact contact@metagentx.com

Our founding discoveries came from the labs of Prof. Takagi and Prof Suga (the 2023 winner of the Wolf Prize in Chemistry), both of whom are deeply involved in our R&D to this day. Their innovations enable a novel class of biologics, called “Neobiologics,” that break existing boundaries in biological drug development and will ultimately better, more cost-effective treatments for patients. Internally and with our partners, we are advancing a robust portfolio of products: 1. cMet agonist to HGF (hepatocyte growth factor) to tackle NASH (non-alcoholic steatohepatitis)/fibrosis; currently in IND enabling studies. 2. TrkB agonist of BDNF (brain-derived neurotrophic factor) to tackle neurodegenerative diseases like Alzheimer's Disease and Parkinson’s Disease; currently in vivo studies. 3. Immuno-oncology bi-specific with T-cell engaging activity and a tumor antigen-specific binder; currently in vitro R&D. 4. Undisclosed assets in various stages. This pipeline builds off our core RaPID System and LassoGraft Technology® (LGT) platforms. The RaPID System selects highly active cyclic peptides that tightly bind to drug-target proteins from our diverse library. These peptides are then genetically grafted onto scaffold proteins using LGT to create Neobiologics. Neobiologics break multiple current boundaries for biologics, such as access across the blood-brain barrier, 3D topological design control, multifunctionality (bi-specific, tri-specific, etc.), wide applicability from AAV capsid modulation to antibodies to therapeutic proteins and superior development speeds that drop development costs significantly. Selected publications 1. Mihara, E et al. Lasso-grafting of macrocyclic peptide pharmacophores yields multi-functional proteins. Nature Communications (2021)2:1543 2. Sakai, K et al. Designing receptor agonists with enhanced pharmacokinetics by grafting macrocyclic peptides into fragment crystallizable regions. Nature Biomedical Engineering 7, 164-176 (2023)

NBHL is committed to discovering First-In-Class medicines for the unmet medical needs with the sophisticated drug discovery platforms ( Monoclonal Antibody for GPCR and Small compounds ). We are looking for the pharmaceutical partners to develop the following projects. We are available for the project-based Drug discovery alliance, using our drug discovery platforms powered by PerkinElmer, and Biotech companies.

Nippon Shinyaku Co., Ltd. is a company that has always devoted serious efforts to make people's lives better. All these efforts have been made based on their strong belief that they should build a healthier future. The company is involved in the manufacture and sale of pharmaceuticals and foodstuffs, and its functional food products find application in various industries such as meat processing, fish processing, dairy product, prepared food, confectionery and bakery, and beverage. Nippon Shinyaku also has research laboratories and a botanical research institute, as well as production and logistics facilities. The company is committed to ESG management and provides information to shareholders and investors through its IR activities. Nippon Shinyaku Co., Ltd. is headquartered in Japan and has branch offices and group companies in various locations.

At Ohara, we are aiming to provide not only treatment options for patients, but also aiming to identify and develop innovative tools to improve the quality of diagnosis, prevention and after care in an effort to become a Total Healthcare Solution company for patients.

OncoTherapy Science, Inc. provides pharmaceutical companies with yielded drug candidates by using outcomes obtained from joint research with universities and companies. These outcomes include oncogene information isolated by comprehensive analysis of genes specifically expressed in cancer cells and functional analysis information of proteins produced by oncogenes and other gene products. We have also been performing research and development business regarding medications.

Creation of optimal nucleic acid medicine for disease treatment with proprietary technology PURMX's solution is a drug discovery seed of small RNA nucleic acid drugs that fine-tune many target genes and deliver unprecedented therapeutic effects. PURMX already possesses a large amount of functional RNA screening data, which is being further expanded. The first stage of innovative nucleic acid medicine seeds is MIRX002. MIRX002 is a nucleic acid medicine for malignant pleural mesothelioma. We have completed non-clinical trials and are conducting investigator-initiated clinical trials at Hiroshima University Hospital starting in 2021.

REPROCELL supports nearly the entire workflow of stem cell research and pre-clinical drug development. Our unique portfolio includes access to human tissues (BioServe) and human tissue testing (Biopta), in addition to stem cell culture media, reprogramming technologies, reagents, and iPSC-derived cell types (Stemgent). With our deep knowledge of stem cell biology, bioengineered (3D) tissue models (Alvetex) cell differentiation, and pharmacology, REPROCELL is a recognized leader in cutting-edge tools and services to accelerate regenerative medicine and drug development. The newly formed REPROCELL Medical business unit is developing a suite of reagents and services to meet the growing need for clinical-grade products and services that are appropriate for regenerative medicine. In addition, our labs offer diagnostic services for a variety of tests related to tissue compatibility and other biomarkers. And finally, REPROCELL also offers a GMP iPSC master cell bank manufacturing service. *** REPROCELL went public on the Japan JASDAQ in June 2013. Stemgent, BioServe and Reinnervate became parts of REPROCELL in 2014. Biopta was then acquired in 2015.

RevolKa is a pioneer of next-generation protein engineering. We are committed to the discovery and development of innovative proteins by leveraging our proprietary artificial intelligence-integrated directed protein evolution technology, called aiProtein®. RevolKa is open to research collaboration opportunities with partners and also co-development of our internal assets. About aiProtein® RevolKa innovatively integrated directed protein evolution with the transformative digital technology, artificial intelligence (AI) to create a proprietary powerful protein engineering technology, called aiProtein®. aiProtein® remarkably accelerates directed protein evolution and enables to create unprecedented engineered proteins. This platform is a robust solution for biologics engineering, for example, to address issues in developability and manufacturability of therapeutic antibodies. aiProtein® enables multi-dimensional simultaneous engineering for protein properties, such as efficacy, affinity, physicochemical properties, immunogenicity, species cross-reactivity, and so on.

Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. It develops drugs in the areas of pain, heart failure, and other diseases. The company has 25 employees as of March 2023 and is headquartered in Minato, Tokyo.

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines